11 January 2019 - - US-based biomedical company EpicGenetics has moved into a new facility that quadruples its capacity, the company said.

EpicGenetics developed and offers the FM/a Test, an FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia.

According to the company, the new facility is 50,000 square feet and located at 11801 West Olympic in Los Angeles.

The move enables the company to expand its lab, support employee growth and facilitate new research initiatives.

In August, the company announced an FDA approved clinical trial that will be held at Massachusetts General Hospital.

The trial will evaluate the potential for BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to reverse fibromyalgia.

EpicGenetics is a privately held biomedical company based in Los Angeles, California that developed and manufactures the FM/a Test.

The company is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers.